Vivos Historical Financial Ratios

VVOS Stock

USD 3.38 0.18 5.62%

Vivos Therapeutics is promptly reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 1.04, Dividend Yield of 0.0, PTB Ratio of 38.75 or Days Sales Outstanding of 5.08 will help investors to properly organize and evaluate Vivos Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vivos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.

About Vivos Financial Ratios Analysis

Vivos TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Vivos Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Vivos financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Vivos Therapeutics history.

Vivos Therapeutics Financial Ratios Chart

At this time, Vivos Therapeutics' Debt To Equity is comparatively stable compared to the past year.

Price To Sales Ratio Days Sales Outstanding Book Value Per Share Average Payables Ev To Sales Revenue Per Share

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Vivos Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Vivos Therapeutics sales, a figure that is much harder to manipulate than other Vivos Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Most ratios from Vivos Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Vivos Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vivos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.At this time, Vivos Therapeutics' Debt To Equity is comparatively stable compared to the past year.

	2023	2024 (projected)
Payables Turnover	2.58	2.62
Days Of Inventory On Hand	1.58E-4	1.5E-4

Payables Turnover Days Of Inventory On Hand

Vivos Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		0.23	0.93	0.1	0.69	0.32	0.53	0.41	0.23	1.0	0.07	0.64	0.53	-0.13	-0.19	-0.72	0.85	0.92	-0.39	-0.85	0.85	-0.9	-0.75	0.82	-0.3	0.54
Ptb Ratio	0.23		0.05	0.05	0.0	0.26	-0.46	0.36	1.0	0.24	0.15	-0.04	-0.46	0.59	-0.82	-0.37	-0.13	0.46	-0.26	0.17	-0.17	-0.42	0.28	0.35	0.25	-0.57
Days Sales Outstanding	0.93	0.05		0.41	0.77	0.25	0.7	0.45	0.05	0.92	0.0	0.82	0.7	-0.23	-0.17	-0.48	0.87	0.83	-0.03	-0.87	0.88	-0.84	-0.8	0.6	-0.36	0.74
Book Value Per Share	0.1	0.05	0.41		0.26	-0.21	0.42	0.5	0.05	0.06	-0.31	0.71	0.42	-0.16	-0.5	0.47	0.06	0.17	0.84	-0.07	0.1	-0.24	-0.06	-0.38	0.04	0.41
Free Cash Flow Yield	0.69	0.0	0.77	0.26		0.66	0.34	0.16	0.0	0.67	0.47	0.38	0.34	0.16	0.13	-0.59	0.79	0.53	0.05	-0.82	0.77	-0.55	-0.8	0.63	-0.58	0.43
Operating Cash Flow Per Share	0.32	0.26	0.25	-0.21	0.66		-0.23	-0.43	0.26	0.33	0.96	-0.2	-0.23	0.77	0.11	-0.74	0.53	0.13	-0.21	-0.52	0.47	-0.08	-0.55	0.64	-0.61	-0.18
Average Payables	0.53	-0.46	0.7	0.42	0.34	-0.23		0.27	-0.46	0.52	-0.35	0.81	1.0	-0.64	0.1	0.05	0.61	0.36	0.2	-0.62	0.65	-0.41	-0.61	0.09	-0.03	0.92
Capex To Depreciation	0.41	0.36	0.45	0.5	0.16	-0.43	0.27		0.36	0.4	-0.65	0.51	0.27	-0.42	-0.53	0.06	-0.03	0.68	0.09	0.01	0.0	-0.75	0.14	0.1	0.46	0.2
Pb Ratio	0.23	1.0	0.05	0.05	0.0	0.26	-0.46	0.36		0.24	0.15	-0.04	-0.46	0.59	-0.82	-0.37	-0.13	0.46	-0.26	0.17	-0.17	-0.42	0.28	0.35	0.25	-0.57
Ev To Sales	1.0	0.24	0.92	0.06	0.67	0.33	0.52	0.4	0.24		0.08	0.62	0.52	-0.13	-0.17	-0.73	0.85	0.92	-0.42	-0.84	0.85	-0.9	-0.75	0.83	-0.3	0.53
Free Cash Flow Per Share	0.07	0.15	0.0	-0.31	0.47	0.96	-0.35	-0.65	0.15	0.08		-0.38	-0.35	0.82	0.23	-0.59	0.36	-0.15	-0.16	-0.35	0.3	0.2	-0.42	0.45	-0.59	-0.3
Roic	0.64	-0.04	0.82	0.71	0.38	-0.2	0.81	0.51	-0.04	0.62	-0.38		0.81	-0.45	-0.38	0.05	0.57	0.6	0.32	-0.56	0.61	-0.63	-0.51	0.09	-0.13	0.81
Inventory Turnover	0.53	-0.46	0.7	0.42	0.34	-0.23	1.0	0.27	-0.46	0.52	-0.35	0.81		-0.64	0.1	0.05	0.61	0.37	0.2	-0.62	0.65	-0.41	-0.61	0.09	-0.04	0.92
Net Income Per Share	-0.13	0.59	-0.23	-0.16	0.16	0.77	-0.64	-0.42	0.59	-0.13	0.82	-0.45	-0.64		-0.27	-0.39	-0.05	-0.16	-0.07	0.07	-0.11	0.21	0.05	0.24	-0.23	-0.67
Days Of Inventory On Hand	-0.19	-0.82	-0.17	-0.5	0.13	0.11	0.1	-0.53	-0.82	-0.17	0.23	-0.38	0.1	-0.27		-0.06	0.16	-0.42	-0.15	-0.2	0.16	0.41	-0.31	0.03	-0.37	0.23
Payables Turnover	-0.72	-0.37	-0.48	0.47	-0.59	-0.74	0.05	0.06	-0.37	-0.73	-0.59	0.05	0.05	-0.39	-0.06		-0.66	-0.61	0.73	0.65	-0.62	0.54	0.6	-0.98	0.4	0.03
Average Inventory	0.85	-0.13	0.87	0.06	0.79	0.53	0.61	-0.03	-0.13	0.85	0.36	0.57	0.61	-0.05	0.16	-0.66		0.6	-0.22	-1.0	1.0	-0.57	-0.98	0.71	-0.63	0.68
Capex To Revenue	0.92	0.46	0.83	0.17	0.53	0.13	0.36	0.68	0.46	0.92	-0.15	0.6	0.37	-0.16	-0.42	-0.61	0.6		-0.38	-0.59	0.6	-0.99	-0.46	0.72	-0.06	0.36
Cash Per Share	-0.39	-0.26	-0.03	0.84	0.05	-0.21	0.2	0.09	-0.26	-0.42	-0.16	0.32	0.2	-0.07	-0.15	0.73	-0.22	-0.38		0.2	-0.19	0.3	0.13	-0.71	-0.01	0.22
Pocfratio	-0.85	0.17	-0.87	-0.07	-0.82	-0.52	-0.62	0.01	0.17	-0.84	-0.35	-0.56	-0.62	0.07	-0.2	0.65	-1.0	-0.59	0.2		-1.0	0.57	0.99	-0.7	0.64	-0.7
Interest Coverage	0.85	-0.17	0.88	0.1	0.77	0.47	0.65	0.0	-0.17	0.85	0.3	0.61	0.65	-0.11	0.16	-0.62	1.0	0.6	-0.19	-1.0		-0.58	-0.98	0.67	-0.63	0.73
Capex To Operating Cash Flow	-0.9	-0.42	-0.84	-0.24	-0.55	-0.08	-0.41	-0.75	-0.42	-0.9	0.2	-0.63	-0.41	0.21	0.41	0.54	-0.57	-0.99	0.3	0.57	-0.58		0.44	-0.68	0.0	-0.39
Pfcf Ratio	-0.75	0.28	-0.8	-0.06	-0.8	-0.55	-0.61	0.14	0.28	-0.75	-0.42	-0.51	-0.61	0.05	-0.31	0.6	-0.98	-0.46	0.13	0.99	-0.98	0.44		-0.63	0.7	-0.7
Days Payables Outstanding	0.82	0.35	0.6	-0.38	0.63	0.64	0.09	0.1	0.35	0.83	0.45	0.09	0.09	0.24	0.03	-0.98	0.71	0.72	-0.71	-0.7	0.67	-0.68	-0.63		-0.32	0.09
Income Quality	-0.3	0.25	-0.36	0.04	-0.58	-0.61	-0.03	0.46	0.25	-0.3	-0.59	-0.13	-0.04	-0.23	-0.37	0.4	-0.63	-0.06	-0.01	0.64	-0.63	0.0	0.7	-0.32		-0.34
Roe	0.54	-0.57	0.74	0.41	0.43	-0.18	0.92	0.2	-0.57	0.53	-0.3	0.81	0.92	-0.67	0.23	0.03	0.68	0.36	0.22	-0.7	0.73	-0.39	-0.7	0.09	-0.34

Click cells to compare fundamentals

Vivos Therapeutics Account Relationship Matchups

Vivos Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	9.79	8.24	2.83	0.58	1.1	1.04
Ptb Ratio	(37.91)	6.36	1.87	1.93	36.91	38.75
Days Sales Outstanding	30.63	42.34	37.16	10.41	5.34	5.08
Book Value Per Share	(5.93)	23.23	30.07	5.22	0.34	0.32
Free Cash Flow Yield	(0.0494)	(0.0539)	(0.38)	(2.22)	(0.84)	(0.88)
Operating Cash Flow Per Share	(10.76)	(7.8)	(18.53)	(21.28)	(9.8)	(10.29)
Capex To Depreciation	0.23	0.17	3.27	1.38	1.29	1.12
Pb Ratio	(37.91)	6.36	1.87	1.93	36.91	38.75
Ev To Sales	10.08	6.94	1.5	0.51	1.12	1.07
Free Cash Flow Per Share	(11.11)	(7.96)	(21.35)	(22.28)	(10.46)	(10.98)
Roic	(13.98)	(0.35)	(0.72)	(4.56)	(19.54)	(18.57)
Net Income Per Share	(21.94)	(12.11)	(23.89)	(24.62)	(11.14)	(11.7)
Payables Turnover	2.53	3.4	4.65	4.26	2.58	2.62
Sales General And Administrative To Revenue	1.42	1.23	1.53	1.81	1.63	1.85
Capex To Revenue	0.0154	0.009203	0.14	0.0577	0.0582	0.11
Cash Per Share	0.95	24.99	28.29	3.82	1.35	1.28
Pocfratio	(20.89)	(18.95)	(3.04)	(0.47)	(1.27)	(1.33)
Capex To Operating Cash Flow	(0.0329)	(0.0212)	(0.15)	(0.0472)	(0.0672)	(0.0706)
Pfcf Ratio	(20.23)	(18.55)	(2.63)	(0.45)	(1.19)	(1.25)
Days Payables Outstanding	144.53	107.43	78.44	85.76	141.58	131.58
Income Quality	0.5	0.47	0.78	0.82	0.88	0.54
Roe	3.7	(0.52)	(0.79)	(4.72)	(33.05)	(31.4)
Ev To Operating Cash Flow	(21.5)	(15.97)	(1.61)	(0.42)	(1.3)	(1.36)
Pe Ratio	(10.24)	(12.2)	(2.35)	(0.41)	(1.12)	(1.17)
Return On Tangible Assets	(2.6)	(0.39)	(0.67)	(2.14)	(1.82)	(1.91)
Ev To Free Cash Flow	(20.81)	(15.64)	(1.4)	(0.4)	(1.22)	(1.28)
Earnings Yield	(0.0976)	(0.082)	(0.42)	(2.45)	(0.9)	(0.94)
Intangibles To Total Assets	0.45	0.12	0.0945	0.23	0.3	0.33
Net Debt To E B I T D A	(0.33)	1.5	1.15	0.0454	(0.0211)	(0.0201)
Current Ratio	0.22	2.61	3.64	0.8	0.34	0.32
Tangible Book Value Per Share	(12.7)	19.19	26.32	1.8	(2.34)	(2.22)
Receivables Turnover	11.92	8.62	9.82	35.06	68.32	71.74
Graham Number	54.1	79.56	127.14	53.75	9.19	8.73
Shareholders Equity Per Share	(5.93)	23.23	30.07	5.22	0.34	0.32
Debt To Equity	(1.26)	0.0763	0.0612	0.0873	1.15	1.21
Capex Per Share	0.35	0.17	2.82	1.0	0.66	0.63
Graham Net Net	(18.48)	15.01	20.22	(5.49)	(6.99)	(6.64)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Vivos Stock Analysis

When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Vivos Historical Financial Ratios

About Vivos Financial Ratios Analysis

Vivos Therapeutics Financial Ratios Chart

Price To Sales Ratio

Book Value Per Share

Average Payables

Ev To Sales

Revenue Per Share

Vivos Therapeutics fundamentals Correlations

Vivos Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vivos Therapeutics fundamentals Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Vivos Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Inventory Turnover	+ 1.0	Average Payables
Interest Coverage	+ 1.0	Average Inventory
Pfcf Ratio	+ 0.99	Pocfratio
Free Cash Flow Per Share	+ 0.96	Operating Cash Flow Per Share

Interest Coverage	- 1.0	Pocfratio
Pocfratio	- 1.0	Average Inventory
Capex To Operating Cash Flow	- 0.99	Capex To Revenue
Pfcf Ratio	- 0.98	Interest Coverage
Pfcf Ratio	- 0.98	Average Inventory
Days Payables Outstanding	- 0.98	Payables Turnover